What are the latest medical insurance regulations for Dasatinib?

Dasatinib was approved by the U.S. FDA in 2006 and subsequently launched in China. Currently, dasatinib has been included in the National Medical Insurance Category B and is limited to patients with chronic myelogenous leukemia who are resistant or intolerant to imatinib.

What are the adverse effects of dasatinib?

The most common adverse reactions (≥15%) in patients receiving dasatinib monotherapy included myelosuppression, fluid retention events, diarrhea, headache, rash, bleeding, dyspnea, fatigue, nausea, and musculoskeletal pain. The most common adverse reactions in pediatric patients receiving dasatinib combination chemotherapy (≥30%) include mucositis, febrile neutropenia, pyrexia, diarrhea, nausea, vomiting, musculoskeletal pain, abdominal pain, cough, headache, rash, fatigue, constipation, cardiac arrest, Arrhythmia, hypertension, edema, infection(bacteria, viruses and fungi), hypotension, decreased appetite, hypersensitivity, dyspnea, epistaxis, peripheral neuropathy and altered state of consciousness. Dermatological adverse effects of dasatinibinclude perifollicular hyperkeratotic rash, acneiform rash, hair depigmentation, vitiligo-like lesions, and panniculitis. The incidence of dasatinib-related rash is estimated to be 23.3%.

How effective is dasatinib?

In theDASISIONclinical trial(NCT00481247), when dasatinib was used as a treatment for chronic phase chronic myelogenous leukemia During first-line treatment, 54% of patients showed a complete cytogenetic response at 3 months. There are generic drugs overseas, produced in India and Bangladesh, and each box costs about four to five hundred. For specific prices, you can consult domestic regular overseas pharmaceutical consulting agencies. If you want to get more high-quality information, you can contact Yaode, and Yaode will do its best to learn more about high-quality overseas drugs for you.

xa0